CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting

Table 2 Clinical trials of CAR-NK presented at ASH 2024

Product	NK cell source	Clinical Trial ID	Clinical Stage	Diseases	Patient number	ORR	CR	CRS	ICANS	Reference
TAK-007	Cord blood	NCT05020015	Phase 2	LBCL	17 ¹	/	800 M, 21% ²	Grade 1(n = 2); Grade 2(n = 1)	None	[10]
TAK-007	Cord blood	NCT05020015	Phase 2	iNHL	9	/	56% ³	Grade 1(n = 2); Grade 2(n = 1)	None	[10]
WU-NK-101	PB	NCT05470140	Phase 1	AML	9	DL ≥ 2, 50% ⁴	/	Grade 1(n = 4)	None	[12]
NKX019	PB	NCT06518668	Phase 1	SLE	/	/	/	/	/	[13]

¹As of the data cut-off date (February 23, 2024), 18 patients with LBCL were enrolled in the study, but 1 LBCL patient in expansion withdrew due to an adverse event before TAK-007 administration
² The study included a dose escalation phase evaluating 2 dose levels (2 × 10⁸ [200 M] and 8 × 10⁸ [800 M] CD19 CAR-NK cells). However, no responses were seen in the 3 LBCL patients who received 200 M TAK-007. 7 of 14 (50%) LBCL patients who received 800 M TAK-007 had a response, including 3 (21%) complete responses
³ Among 9 iNHL patients, 7 (78%) had a response including 5 (56%) complete responses
⁴ Patients received WU-NK-101 treatment at dosage levels of 300 million cells (DL1), 900 million (DL2), and 1.8 billion (DL3), with three patients at each DL. No responses were noted at DL1. At DL ≥ 2 groups, the objective response rate was 50%
AML: acute myeloid leukemia; CAR-NK: chimeric antigen receptor-engineered natural killer; CR: complete response; CRS: cytokine release syndrome; DL:dosage level; ICANS: immune effector cell-associated neurotoxicity syndrome; iNHL: indolent non-Hodgkin lymphoma; LBCL: large B-cell lymphoma; NK: natural killer; OR: objective response; ORR: objective response rate; PB: peripheral blood; SLE: systemic lupus erythematosus

ISSN: 1756-8722